English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12189/12972 (94%)
Visitors : 974216      Online Users : 995
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Community Statistics


    近3年內發表的文件:338(14.01%)
    含全文筆數:2253(93.41%)

    文件下載次數統計
    下載大於0次:2253(100.00%)
    下載大於100次:2253(100.00%)
    檔案下載總次數:1618764(28.86%)

    最後更新時間: 2024-12-04 17:40

    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 831-840 of 2412. (242 Page(s) Totally)
    << < 79 80 81 82 83 84 85 86 87 88 > >>
    View [10|25|50] records per page

    DateTitleRelation
    2018-02 Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.
    2018-02 Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459.
    2018-02 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90.
    2018-02 Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388.
    2018-02 Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379.
    2018-02 Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410.
    2018-01-20 Patterns of age-specific socioeconomic inequalities in net survival for common cancers in Taiwan, a country with universal health coverage Cancer Epidemiology. 2018 Jan 20;53:42-48.
    2018-01-19 Association between fetal exposure to phthalate endocrine disruptor and genome-wide DNA methylation at birth Environmental Research. 2018 Jan 19;162:261-270.
    2018-01 First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis Gut. 2018 Jan;67(1):20-27.
    2018-01 Prior gastroscopy and mortality in patients with gastric cancer: A matched retrospective cohort study Gastrointestinal Endoscopy. 2018 Jan;87(1):119-127.e3.

    Showing items 831-840 of 2412. (242 Page(s) Totally)
    << < 79 80 81 82 83 84 85 86 87 88 > >>
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback